Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Analysts

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been assigned an average recommendation of “Hold” from the eight brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $5.25.

Separately, Wells Fargo & Company raised their target price on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a report on Monday, December 15th.

Maravai LifeSciences Trading Up 3.4%

Maravai LifeSciences stock opened at $3.08 on Friday. Maravai LifeSciences has a 1 year low of $1.66 and a 1 year high of $4.30. The firm’s 50-day moving average is $3.47 and its 200-day moving average is $3.16. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.56 and a current ratio of 5.29. The company has a market cap of $787.59 million, a P/E ratio of -3.67 and a beta of 0.39.

Insider Buying and Selling at Maravai LifeSciences

In related news, Director Gregory T. Lucier purchased 48,528 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The shares were acquired at an average price of $3.67 per share, with a total value of $178,097.76. Following the acquisition, the director owned 155,123 shares in the company, valued at approximately $569,301.41. This trade represents a 45.53% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.11% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Several large investors have recently added to or reduced their stakes in the stock. Barclays PLC lifted its stake in Maravai LifeSciences by 3.0% in the fourth quarter. Barclays PLC now owns 172,281 shares of the company’s stock valued at $560,000 after buying an additional 5,057 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Maravai LifeSciences by 12.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock worth $112,000 after acquiring an additional 5,160 shares during the period. Performa Ltd US LLC lifted its position in Maravai LifeSciences by 33.3% in the 2nd quarter. Performa Ltd US LLC now owns 22,990 shares of the company’s stock valued at $55,000 after purchasing an additional 5,740 shares during the last quarter. Epacria Capital Partners LLC boosted its stake in Maravai LifeSciences by 6.8% during the 3rd quarter. Epacria Capital Partners LLC now owns 100,078 shares of the company’s stock valued at $287,000 after purchasing an additional 6,384 shares during the period. Finally, Ethic Inc. boosted its stake in Maravai LifeSciences by 62.8% during the 3rd quarter. Ethic Inc. now owns 16,951 shares of the company’s stock valued at $49,000 after purchasing an additional 6,540 shares during the period. 50.25% of the stock is owned by institutional investors and hedge funds.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.